Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

ABIONYX Pharma SA (609) AI Stock Analysis

0 Followers
DE:609

ABIONYX Pharma SA

(Frankfurt:609)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Specialized HDL biology platformThe company has a clearly defined therapeutic platform centered on apoA-I and HDL biology, giving its research effort a coherent scientific focus. A specialized platform can support development across multiple severe inflammatory and infectious indications if clinical work continues to validate the approach.
Negative Factors
Large operating losses and weak marginsVery large operating losses relative to revenue show that the current business has not reached economic scale. The sharp gross-margin deterioration further weakens the prospect of near-term self-funded growth, making improved economics dependent on stronger revenue or substantial cost restructuring.

ABIONYX Pharma SA (609) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:609-60.66%EWG+6.38%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 71.98M
Dividend Yield
―
Average Volume (3M)
6,633
Price to Earnings (P/E)
-7.7
Beta (1Y)
-0.30
Revenue Growth
-10.38%
EPS Growth
-72.05%
Country
Germany
Employees
49
Sector
General
Sector Strength
55
Industry
Biotechnology

ABIONYX Pharma SA Business Overview & Revenue Model

Company Description

ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This...

ABIONYX Pharma SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:609 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
FR:SIGHTFR:SIGHT46NeutralEUR 18.44M-1.0252.39%―-610.31%43.88%
FR:ALSENFR:ALSEN41NeutralEUR 81.46M-1.95-54.15%――6.26%

* General Sector Average

Performance Comparison

-50%0%50%100%DE:609FR:ALCOXFR:SIGHTFR:ALSENDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:609 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:609ABIONYX Pharma SA1.53-2.38-60.81%
FR:ALCOXNicox SA0.30-0.04-10.84%
FR:SIGHTGenSight Biologics0.07-0.04-35.09%
FR:ALSENSensorion SAS8.28-9.02-52.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.